Status:
COMPLETED
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy
Lead Sponsor:
University of Campania Luigi Vanvitelli
Conditions:
Iron Overload
Eligibility:
All Genders
2+ years
Brief Summary
Iron overload is a leading cause of morbidity and mortality in transfusion-dependent patients. Deferasirox is the most promising iron chelator agent in several clinical scenarios. The investigators pr...
Eligibility Criteria
Inclusion
- Transfusion- dependent patients (\> 2 years);
- Ongoing deferasirox therapy during the study period;
- ≥ 2 Magnetic Resonance scans (one at baseline and at least one post baseline - as per clinical need) during study period (this criteria is not mandatory for patients undergoing only the endocrine subanalysis and participating only to the cardiac analysis);
- Available medical history including relevant clinical and laboratory data (e.g serum ferritin, liver function tests, renal function tests, endocrine parameters ) at baseline before starting deferasirox treatment
Exclusion
- Non transfusion- dependent patients;
- Other chelation therapy than deferasirox;
- Absence of complete medical history as above specified
Key Trial Info
Start Date :
March 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01874405
Start Date
March 1 2003
End Date
October 1 2012
Last Update
June 11 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.